Chinook investor relations
WebChinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. Changing the Course of Kidney Care™ Read More Web23 hours ago · Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Noopur Liffick Senior Vice President, Investor Relations & Corporate Communications [email protected] [email protected]
Chinook investor relations
Did you know?
WebNoopur Liffick is Senior Vice President of Investor Relations and Corporate Communications at Chinook Therapeutics. With over 17 years of investor relations, … Web1 day ago · Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective ...
WebOct 15, 2024 · For more information on these and other abstracts, please visit the ASN Kidney Week 2024 website and Abstract Supplement. Investor Conference Call Details To access the call, please dial (844 ... WebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused …
WebNoopur Liffick is Senior Vice President of Investor Relations and Corporate Communications at Chinook Therapeutics. With over 17 years of investor relations, communications and financial services experience in the healthcare industry and over $350 million in capital raised, Noopur has established a proven track record of managing … WebMay 20, 2024 · Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Noopur Liffick Vice President, Investor Relations & Corporate Communications [email protected]. [email protected]
Web2 days ago · To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. …
WebMay 25, 2024 · SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of … church of scotland glasgow churchesWebJan 31, 2024 · INVESTORS OVERVIEW. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung … church of scotland gorbals glasgowWebFeb 27, 2024 · Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Noopur Liffick church of scotland gibraltarWebNov 10, 2024 · Mr. Bjerkholt joins Chinook from Aimmune Therapeutics, Inc., where he most recently served as CFO overseeing financial reporting, budgeting, internal controls, investor relations, business ... church of scotland guild national convenerschurch of scotland general assembly 2020Web2 days ago · SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor … church of scotland guild gatheringWebApr 11, 2024 · Investor Relations ... About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s ... dewayne little